Nektar Therapeutics

NasdaqCM:NKTR Stock Report

Market Cap: US$388.4m

Nektar Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

NasdaqCM:NKTR Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
19 May 25SellUS$15,549Howard RobinIndividual1,547.2US$10.05
19 May 25SellUS$6,697Mark WilsonIndividual666.4US$10.05
19 May 25SellUS$7,177Jonathan ZalevskyIndividual714.13US$10.05
19 Feb 25SellUS$24,012Howard RobinIndividual1,584.93US$15.15
19 Feb 25SellUS$11,150Mark WilsonIndividual736US$15.15
19 Feb 25SellUS$10,403Jonathan ZalevskyIndividual686.67US$15.15
24 Dec 24SellUS$14,738Mark WilsonIndividual1,104US$13.35
23 Dec 24SellUS$30,062Mark WilsonIndividual2,226.8US$13.50
19 Dec 24SellUS$48,048Jonathan ZalevskyIndividual3,407.67US$14.10
18 Dec 24SellUS$131,650Howard RobinIndividual8,802US$15.15
19 Nov 24SellUS$6,471Mark WilsonIndividual427.13US$15.15
19 Nov 24SellUS$7,863Jonathan ZalevskyIndividual519US$15.15
19 Nov 24SellUS$16,441Howard RobinIndividual1,085.2US$15.15
19 Aug 24SellUS$8,788Jonathan ZalevskyIndividual457.73US$19.20
19 Aug 24SellUS$19,048Howard RobinIndividual992.07US$19.20
19 Aug 24SellUS$7,233Mark WilsonIndividual376.73US$19.20

Insider Trading Volume

Insider Buying: NKTR insiders have only sold shares in the past 3 months.


Ownership Breakdown

What is the ownership structure of NKTR?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders172,9060.999%
Hedge Funds2,209,45812.8%
General Public5,764,87433.3%
Institutions9,153,82352.9%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 41%.


Top Shareholders

Top 25 shareholders own 56.33% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
8.29%
Charles Schwab Investment Management, Inc.
1,434,457US$32.2m1,400%no data
7.38%
BVF Partners L.P.
1,276,595US$28.7m0%0.87%
5.39%
Millennium Management LLC
932,863US$20.9m511%0.02%
4.74%
The Vanguard Group, Inc.
820,646US$18.4m-0.15%no data
3%
Nantahala Capital Management, LLC
519,270US$11.7m-0.27%0.7%
2.81%
Acadian Asset Management LLC
486,782US$10.9m1.4%0.02%
2.56%
Eventide Asset Management, LLC
443,333US$10.0m0%0.17%
2.27%
Goldman Sachs Group, Investment Banking and Securities Investments
392,965US$8.8m1,400%no data
2.06%
PRIMECAP Management Company
356,972US$8.0m-3.35%0.01%
1.81%
Renaissance Technologies LLC
313,452US$7.0m20.2%0.01%
1.78%
Almitas Capital LLC
307,391US$6.9m401%1.15%
1.54%
Geode Capital Management, LLC
267,275US$6.0m1.3%no data
1.54%
TCG Crossover Management, LLC
266,666US$6.0m0%0.41%
1.42%
Woodline Partners LP
246,125US$5.5m-25.8%0.03%
1.38%
AQR Capital Management, LLC
239,606US$5.4m331%no data
1.26%
State Street Global Advisors, Inc.
217,219US$4.9m-0.42%no data
1.17%
BlackRock, Inc.
203,017US$4.6m-80.6%no data
1.16%
Jacobs Levy Equity Management Inc
200,528US$4.5m14.5%0.02%
0.86%
Exome Asset Management LLC
148,830US$3.3m261%2.69%
0.84%
22NW, LP
146,116US$3.3m0%1.54%
0.64%
Mackenzie Financial Corporation
110,583US$2.5m253%no data
0.62%
Wells Fargo & Company, Private Banking and Investment Banking Arm
107,152US$2.4m1,400%no data
0.62%
Mirae Asset Global Investments Co., Ltd.
106,886US$2.4m1,400%no data
0.61%
Ikarian Capital, LLC
105,301US$2.4m-22.2%0.71%
0.55%
Two Sigma Investments, LP
95,673US$2.1m-6.65%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/08/07 22:15
End of Day Share Price 2025/08/07 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nektar Therapeutics is covered by 35 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Richard SilverBarclays
Aydin HuseynovBenchmark Company
George FarmerBMO Capital Markets Equity Research